Tecrea

Tecrea Ltd is a biotechnology company founded in 2012 as a spin-out from the Royal Veterinary College, University of London. The company specializes in molecular science and nanotechnology, having developed a patented platform called Nanocin. This platform utilizes nanoparticle-forming technology to rapidly self-assemble molecules and package them into nanoparticles, facilitating the delivery of nucleic acids, proteins, peptides, and small molecules into both mammalian and bacterial cells. A key differentiator of the Nanocin technology is its high transfection efficiency coupled with extremely low toxicity, maintaining over 99 percent cell viability. Furthermore, the technology is designed to be GMP compliant and fully translatable from academic research environments directly into clinical applications.

The company's innovations address critical challenges in drug development, life-cycle extension, and cell delivery, offering researchers and pharmaceutical partners tools that improve accuracy, speed, and yield without compromising experimental integrity. By providing these specialized reagents and delivery systems, Tecrea supports the biomedical community in developing new treatments for human and animal health. The company works through various collaborations with biotechnology, pharmaceutical, and academic partners to help overcome the limitations of existing therapies and advance potential drug reformulations. Operating out of the London BioScience Innovation Centre, Tecrea combines expertise in bioprocessing, transfection, and drug formulation to empower advances in healthcare science.